Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Cirius Therapeutics
161 E Michigan Ave, Suite 400
Phone: 616-450-1613
http://ciriustx.com

Cirius Therapeutics, formerly known as Octeta Therapeutics, is a clinical-stage pharmaceutical company focused on developing therapies to treat liver disease. The company's lead product is MSDC-0602K, a second-generation insulin sensitizer for the treatment of NASH. Cirius is actively enrolling patients in a Phase 2b clinical trial called the EMMINENCE trial, to evaluate MSDC-0602K in patients with NASH and liver fibrosis. For additional information on the EMMINENCE trial, please visit clinicatrials.gov using the identifier NCT02784444.

Key Contact
Name
Bob Baltera
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
04/14/17 $40,000,000 Series A Adams Street Partners
Frazier Healthcare
Novo A/S
Renaissance Venture Capital Fund
undisclosed


Featured Reading